Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About TMO Interactive Breakdown Better Bets vs. TMO Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Thermo Fisher Scientific (TMO)

Market Price (10/26/2025): $570.01 | Market Cap: $215.5 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Thermo Fisher Scientific (TMO)

Market Price (10/26/2025): $570.01
Market Cap: $215.5 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%, CFO LTM is 7.6 Bil, FCF LTM is 6.2 Bil		 Weak multi-year price returns
2Y Excs Rtn is -37%, 3Y Excs Rtn is -70%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 29x, P/EPrice/Earnings or Price/(Net Income) is 33x
1 Low stock price volatility
Vol 12M is 33%		  Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.3%
0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%, CFO LTM is 7.6 Bil, FCF LTM is 6.2 Bil
1 Low stock price volatility
Vol 12M is 33%
2 Weak multi-year price returns
2Y Excs Rtn is -37%, 3Y Excs Rtn is -70%
3 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 29x, P/EPrice/Earnings or Price/(Net Income) is 33x
4 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.3%

Market Valuation & Key Metrics

TMOS&P 500
REVENUE GROWTHPOOR
Rev LTM ($ Bil)43.2
Rev Chg Q3.0%6.4%
Rev Chg LTM2.0%5.3%
Rev Chg 3Y Avg0.3%5.4%
PROFITABILITYFAIR
Op Inc LTM ($ Bil)7.9
CFO LTM ($ Bil)7.6
Net Inc LTM ($ Bil)6.6
Op Mgn LTM18.2%18.7%
CFO/Rev LTM17.5%20.5%
Net Inc Mgn15.2%12.7%
VALUATIONHIGH
P/S5.03.3
P/CFO28.416.1
P/FCF34.920.9
P/E32.724.0
STABILITYGOOD
Debt/Equity0.160.21
Cash/Assets0.060.07

TMO Stock

   
   
   
   
   
   
   

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
TMO Return44%44%-17%-3%-2%10%79%
Peers Return28%29%-20%34%4%25%134%
S&P 500 Return16%27%-19%24%23%15%110%

Monthly Win Rates [3]
TMO Win Rate67%75%42%58%50%44% 
Peers Win Rate50%45%32%50%48%49% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
TMO Max Drawdown-21%-6%-27%-22%-5%-25% 
Peers Max Drawdown-26%-3%-28%-3%-6%-34% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: MU, AMAT, TXN, ADI, BDMD. See TMO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/24/2025 (YTD)

How Low Can It Go

Unique KeyEventTMOS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-35.3%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven54.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-24.9%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven33.2%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven35 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-17.3%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven20.9%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven53 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-53.9%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven117.0%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven909 days1480 days

Compare to MU, AMAT, TXN, ADI, BDMD


In The Past

Thermo Fisher Scientific's stock fell -35.3% during the 2022 Inflation Shock from a high on 12/31/2021. A -35.3% loss requires a 54.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Thermo Fisher Scientific (TMO)

Better Bets than Thermo Fisher Scientific (TMO)

 TMOBetter Performance than TMO
MetricValueIndustry (Life Sciences Tools & Services)
Rev Chg LTM2.0%DHR (2.2%), A (4.5%), IQV (3.6%), MTD (3.1%), NTRA (44.4%)
Rev Chg 3Y Avg0.3%A (0.8%), IQV (3.6%), NTRA (39.7%), WAT (1.7%), MEDP (19.9%)
Op Mgn LTM18.2%DHR (19.0%), A (21.3%), MTD (28.4%), WAT (27.7%), MEDP (21.5%)
CFO/Rev LTM17.5%DHR (26.0%), A (22.0%), MTD (24.6%), WAT (24.5%), MEDP (30.2%)
FCF/Rev LTM14.3%DHR (20.7%), A (16.0%), MTD (21.9%), WAT (20.3%), MEDP (28.7%)
Total Yield3.0%A (3.6%), IQV (3.3%), WAT (3.1%), ILMN (8.0%), ICLR (4.4%)
 TMOBetter Performance than TMO
MetricValueAll Other Sectors
Rev Chg LTM2.0%NVDA (71.6%), AAPL (6.0%), MSFT (14.9%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg0.3%NVDA (92.0%), AAPL (1.8%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM18.2%NVDA (58.1%), AAPL (31.9%), MSFT (45.6%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM17.5%NVDA (46.6%), AAPL (26.6%), MSFT (48.3%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM14.3%NVDA (43.6%), AAPL (23.5%), MSFT (25.4%), GOOGL (18.0%), META (30.7%)
Total Yield3.0%MSFT (3.2%), GOOGL (4.0%), META (3.8%), WMT (3.4%), JPM (6.7%)
 Best Bets In Health Care Sector
 TMORPRX HALO CPRX LNTH PBH EW AVTR ILMN HCA THC
What You Pay           
P/E32.915.514.412.314.214.510.815.312.517.912.9
P/EBIT25.88.211.310.59.79.326.610.410.49.85.0
What You Get           
Rev Chg Q3.0%7.7%40.8%19.4%-4.1%-6.6%11.9%-1.1%-4.8%6.4%3.2%
Rev Chg LTM2.0%3.0%35.0%28.5%5.7%0.6%9.1%-2.3%-3.3%6.4%-1.1%
Rev Chg 3Y Avg0.3%0.8%35.5%49.9%34.3%0.8%3.0%-4.3%-3.0%6.6%2.7%
FCF/Rev 3Y Avg15.5%113.4%43.4%38.9%26.1%21.6%11.9%9.7%9.0%8.4%7.1%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Thermo Fisher Scientific Earnings Notes  
2Day 9 of Gains Streak for Thermo Fisher Scientific Stock with 9.1% Return (vs. 10% YTD) [10/24/2025]Notification 
3Day 8 of Gains Streak for Thermo Fisher Scientific Stock with 9% Return (vs. 10% YTD) [10/23/2025]Notification 
4Thermo Fisher Scientific Stock Up 25% in One Month, Now Is Not The Time To Buy The StockBuy or Fear 
5Day 7 of Gains Streak for Thermo Fisher Scientific Stock with 8.1% Return (vs. 9.3% YTD) [10/22/2025]Notification 
6Thermo Fisher Scientific vs Mettler-Toledo International: Which Stock Could Rally?Counter-Intuitive Comparisons 
7Better Value & Growth: IQV, BVS Top Thermo Fisher Scientific StockActionable 
8How Thermo Fisher Scientific Stock Gained 30%  
9Thermo Fisher Scientific Stock Rallied 25% - Have You Assessed the RiskReturn 
10After TMO's 15% Climb in a Month, JNJ Looks Like the Stronger Long-Term PlayCounter-Intuitive Comparisons 
11ARTICLES  
12Thermo Fisher Scientific Stock Rockets 9.1% With 9-Day Winning Streak October 25th, 2025
13Thermo Fisher Scientific Stock Rockets 9% With 8-Day Winning Streak October 24th, 2025
14Thermo Fisher Scientific Stock To $398? October 23rd, 2025
15Thermo Fisher Scientific Stock On Fire: Up 8.1% With 7-Day Winning Streak October 23rd, 2025
16TMO Shares Rally 14% In A Week, Now Is Not The Time To Buy The Stock October 3rd, 2025
Title
0DASHBOARDS
1Thermo Fisher Scientific Stock Rockets 9.1% With 9-Day Winning Streak
2Thermo Fisher Scientific Stock Rockets 9% With 8-Day Winning Streak
3Thermo Fisher Scientific Stock To $398?
4Thermo Fisher Scientific Stock On Fire: Up 8.1% With 7-Day Winning Streak
5TMO Shares Rally 14% In A Week, Now Is Not The Time To Buy The Stock
6ARTICLES
7Thermo Fisher Scientific Earnings Notes
8Day 9 of Gains Streak for Thermo Fisher Scientific Stock with 9.1% Return (vs. 10% YTD) [10/24/2025]
9Day 8 of Gains Streak for Thermo Fisher Scientific Stock with 9% Return (vs. 10% YTD) [10/23/2025]
10Thermo Fisher Scientific Stock Up 25% in One Month, Now Is Not The Time To Buy The Stock
11Day 7 of Gains Streak for Thermo Fisher Scientific Stock with 8.1% Return (vs. 9.3% YTD) [10/22/2025]
12Thermo Fisher Scientific vs Mettler-Toledo International: Which Stock Could Rally?
13Better Value & Growth: IQV, BVS Top Thermo Fisher Scientific Stock
14How Thermo Fisher Scientific Stock Gained 30%
15Thermo Fisher Scientific Stock Rallied 25% - Have You Assessed the Risk
16After TMO's 15% Climb in a Month, JNJ Looks Like the Stronger Long-Term Play

Trade Ideas

Select past ideas related to TMO. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.5%3.5%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.4%6.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		19.5%19.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		17.1%17.1%-8.0%
TMO_4302025_Monopoly_xInd_xCD_Getting_Cheaper04302025TMOThermo Fisher ScientificMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		33.7%33.7%-8.9%
TMO_9302022_Monopoly_xInd_xCD_Getting_Cheaper09302022TMOThermo Fisher ScientificMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		13.8%0.1%-4.4%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.5%3.5%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.4%6.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		19.5%19.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		17.1%17.1%-8.0%
TMO_4302025_Monopoly_xInd_xCD_Getting_Cheaper04302025TMOThermo Fisher ScientificMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		33.7%33.7%-8.9%
TMO_9302022_Monopoly_xInd_xCD_Getting_Cheaper09302022TMOThermo Fisher ScientificMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		13.8%0.1%-4.4%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1498.4%344.0%
2PRAXPraxis Precision Medicines253.2%126.1%
3NVTSNavitas Semiconductor116.1%294.1%
4SNDKSanDisk97.4% 
5UAMYUnited States Antimony90.3%578.5%
6GRALGRAIL85.2%400.8%
7BALYBallys82.9%6.8%
8ORKAOruka Therapeutics81.1%40.5%
9INBXInhibrx Biosciences79.9%272.0%
10CIFRCipher Mining77.2%345.3%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1VGVenture Global-35.7% 
2PMIPicard Medical-35.3%8328.6%
3SOCSable Offshore-33.7%-41.7%
4FWRDForward Air-28.9%-39.0%
5FLYFirefly Aerospace-28.5% 
6ITGRInteger-28.4%-45.0%
7USNAUsana Health Sciences-26.5%-42.0%
8HTZHertz Global-26.3%41.5%
9RCReady Capital-25.1%-50.3%
10ULHUniversal Logistics-24.8%-61.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Thermo Fisher Scientific

Financials

TMOMUAMATTXNADIBDMDMedian
NameThermo F.Micron T.Applied .Texas In.Analog D.Baird Me. 
Mkt Price572.50219.02228.75169.13238.011.40223.88
Mkt Cap216.4245.7182.5153.7117.7-182.5
Rev LTM43,21137,37828,61317,26610,387-28,613
Op Inc LTM7,8609,8098,6236,0122,630-7,860
FCF LTM6,1701,6685,8232,0803,678-3,678
FCF 3Y Avg6,662-1,4436,4571,7323,439-3,439
CFO LTM7,57817,5257,7056,8974,162-7,578
CFO 3Y Avg8,2069,1977,7886,5604,310-7,788

Growth & Margins

TMOMUAMATTXNADIBDMDMedian
NameThermo F.Micron T.Applied .Texas In.Analog D.Baird Me. 
Rev Chg LTM2.0%48.9%6.6%9.9%7.1%-7.1%
Rev Chg 3Y Avg0.3%20.3%4.4%-4.6%-0.6%-0.3%
Rev Chg Q3.0%46.0%7.7%14.2%24.6%-14.2%
QoQ Delta Rev Chg LTM0.7%10.5%1.9%3.5%5.8%-3.5%
Op Mgn LTM18.2%26.2%30.1%34.8%25.3%-26.2%
Op Mgn 3Y Avg17.4%-1.1%29.4%38.0%27.5%-27.5%
QoQ Delta Op Mgn LTM-0.1%3.7%0.5%-0.1%1.8%-0.5%
CFO/Rev LTM17.5%46.9%26.9%39.9%40.1%-39.9%
CFO/Rev 3Y Avg19.1%30.3%28.5%38.6%39.5%-30.3%
FCF/Rev LTM14.3%4.5%20.4%12.0%35.4%-14.3%
FCF/Rev 3Y Avg15.5%-11.5%23.7%10.2%31.5%-15.5%

Valuation

TMOMUAMATTXNADIBDMDMedian
NameThermo F.Micron T.Applied .Texas In.Analog D.Baird Me. 
Mkt Cap216.4245.7182.5153.7117.7-182.5
P/S5.06.66.48.911.3-6.6
P/EBIT25.824.319.924.744.3-24.7
P/E32.928.826.730.560.1-30.5
P/CFO28.614.023.722.328.3-23.7
Total Yield3.0%3.7%4.5%6.5%3.3%-3.7%
Dividend Yield0.0%0.2%0.7%3.2%1.6%-0.7%
FCF Yield 3Y Avg3.6%-2.4%4.4%1.1%3.2%-3.2%
D/E0.20.10.00.10.1-0.1
Net D/E0.10.0-0.00.10.0-0.0

Returns

TMOMUAMATTXNADIBDMDMedian
NameThermo F.Micron T.Applied .Texas In.Analog D.Baird Me. 
1M Rtn24.7%39.7%14.6%-7.1%-3.8%-39.9%5.4%
3M Rtn19.8%97.0%23.5%-7.9%4.9%-31.4%12.3%
6M Rtn35.2%175.0%51.8%5.5%23.4%-75.5%29.3%
12M Rtn3.6%103.8%23.9%-15.8%5.2%-54.5%4.4%
3Y Rtn14.8%301.5%166.8%17.2%77.5%-77.5%
1M Excs Rtn21.8%36.9%11.8%-9.9%-6.7%-42.7%2.5%
3M Excs Rtn11.9%90.7%14.3%-16.3%-2.7%-39.6%4.6%
6M Excs Rtn12.3%152.0%28.9%-17.4%0.4%-98.4%6.4%
12M Excs Rtn-18.1%87.9%10.2%-26.3%-8.3%-73.0%-13.2%
3Y Excs Rtn-69.6%236.0%120.5%-62.6%-6.2%--6.2%

Comparison Analyses

Title
0TMO or TXN - With 7.6% Return Forecast, TXN Probably Deserves Your Money
1MU Could Deliver 35% Returns And Outperform TMO
2AMAT Looks Stronger Than TMO With 7.0% Return Potential
3Thermo Fisher Scientific vs. NVIDIA: With Return Forecast Of 62%, NVIDIA Is A Better Bet
4Thermo Fisher Scientific vs. Abbott Laboratories: With Return Forecast Of 21%, Thermo Fisher Scientific Is A Better Bet
5Thermo Fisher Scientific vs. Tesla: With Return Forecast Of 58%, Tesla Is A Better Bet
6Thermo Fisher Scientific vs. Accenture: With Return Forecast Of 26%, Thermo Fisher Scientific Is A Better Bet
7Thermo Fisher Scientific vs. Cisco: Similar Market Cap, But Cisco Is A Better Bet
8Thermo Fisher Scientific vs. Chevron: Similar Market Cap, But Chevron Is A Better Bet
9Thermo Fisher Scientific vs. Analog Devices: Industry Peers, But Thermo Fisher Scientific Is A Better Bet

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/28/20253/29/202512/31/20249/30/20246/29/20243/30/202412/31/20239/30/20237/1/20234/1/202312/31/202210/1/2022
Filing Date8/1/20255/2/20252/20/202511/1/20248/2/20245/3/20242/22/202411/3/20238/4/20235/5/20232/23/202311/4/2022
Key Financials Quarterly            
Total Revenue10,85410,36411,39510,59810,54110,34510,88610,57410,68710,71011,45010,677
Ebitda2,7992,6283,0002,8372,9102,7882,9692,9772,6112,5222,8942,612
Operating Income1,9161,8152,2451,8841,8971,6911,9341,9481,7611,6751,9161,743
Net Income1,6171,5071,8301,6301,5481,3281,6301,7151,3611,2891,5761,495
EPS4.283.994.794.264.053.474.224.443.533.344.033.82
Key Financials TTM            
Total Revenue TTM43,21142,89842,87942,37042,34642,49242,85743,42143,52443,80744,91544,167
Ebitda TTM11,26411,37511,53511,50411,64411,34511,07911,00410,63910,92911,94211,754
Operating Income TTM7,8607,8417,7177,4067,4707,3347,3187,3007,0957,3598,5079,175
Net Income TTM6,5846,5156,3366,1366,2216,0345,9955,9415,7216,0246,9507,032
Growth Rates Quarterly            
Total Revenue Growth3.0%0.2%4.7%0.2%-1.4%-3.4%-4.9%-1.0%-2.6%-9.4%7.0%14.4%
EBITDA Growth-3.8%-5.7%1.0%-4.7%11.5%10.5%2.6%14.0%-10.0%-28.7%6.9%-10.9%
Operating Income Growth1.0%7.3%16.1%-3.3%7.7%1.0%0.9%11.8%-13.0%-40.7%-25.9%-24.1%
Net Income Growth4.5%13.5%12.3%-5.0%13.7%3.0%3.4%14.7%-18.2%-41.8%-4.9%-21.4%
Margins Quarterly            
EBITDA Margin25.8%25.4%26.3%26.8%27.6%27.0%27.3%28.2%24.4%23.5%25.3%24.5%
Operating Income Margin17.7%17.5%19.7%17.8%18.0%16.3%17.8%18.4%16.5%15.6%16.7%16.3%
Net Income Margin14.9%14.5%16.1%15.4%14.7%12.8%15.0%16.2%12.7%12.0%13.8%14.0%
Cash & Debt            
Total Cash6,3905,9475,5706,6458,8237,2508,0806,1513,1333,4828,5242,919
Total Debt35,22934,18931,27535,31335,40535,60834,91735,28434,00835,25734,48829,160
Net Debt / (Cash)28,83928,24225,70528,66826,58228,35826,83729,13330,87531,77525,96426,241
Cash Flows Quarterly            
FCF from Operations1,3997233,2902,1661,9601,2513,7232,4141,5407293,4871,937
Cash Flows TTM            
FCF from Operations TTM7,5788,1398,6679,1009,3488,9288,4068,1707,6937,6819,1548,124
Returns to Shareholders Quarterly            
Dividends162149149150149135136135135117117118
Share Repurchases-02,0001,000-0-03,000-0-0-03,0001,000-0
Return on Invested Capital (ROIC) Quarterly            
ROIC25.1%24.2%32.2%24.8%26.5%19.6%26.6%25.9%22.0%20.4%26.6%26.1%
Return on Invested Capital (ROIC) TTM            
ROIC TTM25.6%25.9%27.2%23.4%25.7%23.8%26.0%23.8%21.9%21.6%29.8%31.7%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Laboratory Products and Biopharma Services23,04122,51114,86212,24510,599
Life Sciences Solutions9,97713,53215,63112,1686,856
Analytical Instruments7,2636,6246,0695,1245,522
Specialty Diagnostics4,4054,7635,6595,3433,718
Elimination of intersegment revenues-1,829-2,515-3,010-2,662-1,153
Total42,85744,91539,21132,21825,542


Operating Income by Segment
$ Mil20242023202220212020
Life Sciences Solutions3,4205,5827,8176,1092,446
Laboratory Products and Biopharma Services3,3582,8721,8441,2711,324
Analytical Instruments1,9081,5071,1978081,273
Specialty Diagnostics1,1241,0241,2801,368930
Selling, general and administrative expenses adjustments-59-37-14410-62
Cost of revenues adjustments-95-46-8-6-17
Restructuring and other costs-459-114-197-99413
Amortization of acquisition-related intangible assets-2,338-2,395-1,761-1,667-1,713
Total6,8598,39310,0287,7944,594


Assets by Segment
$ Mil20242023202220212020
Unallocated amounts85,31483,340   
Laboratory Products and Biopharma Services6,3506,42852,63922,71121,761
Life Sciences Solutions3,1863,84522,75120,20918,306
Analytical Instruments2,7262,4659,6929,7739,896
Specialty Diagnostics1,1501,0766,0106,5345,867
Corporate/Other  4,0319,8252,551
Total98,72697,15495,12369,05258,381


Price Behavior

TMO Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta1.731.051.411.010.860.89
Up Beta3.731.811.660.910.860.97
Down Beta0.290.401.261.110.940.91
Up Capture87%87%167%82%47%38%
Bmk +ve Days13233574144420
Stock +ve Days7193161115372
Down Capture245%99%98%123%99%98%
Bmk -ve Days8192952107330
Stock -ve Days14233365136379

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity3,908,166
Short Interest: % Change Since 9302025-8.4%
Average Daily Volume2,450,214
Days-to-Cover Short Interest1.60
Basic Shares Quantity378,000,000
Short % of Basic Shares1.0%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/22/20251.7%  
7/23/20259.1%12.8%15.7%
4/23/2025-0.7%-1.7%-8.4%
1/30/20256.8%2.5%-6.9%
10/23/2024-1.7%-6.6%-12.5%
7/24/20244.1%11.4%10.5%
4/24/20240.5%-1.0%2.8%
1/31/2024-5.0%-1.2%0.5%
...
SUMMARY STATS   
# Positive151212
# Negative91212
Median Positive2.7%4.3%5.2%
Median Negative-2.8%-1.7%-6.9%
Max Positive9.1%12.8%15.7%
Max Negative-5.5%-6.6%-12.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025801202510-Q 6/28/2025
3312025502202510-Q 3/29/2025
12312024220202510-K 12/31/2024
93020241101202410-Q 9/30/2024
6302024802202410-Q 6/29/2024
3312024503202410-Q 3/30/2024
12312023222202410-K 12/31/2023
93020231103202310-Q 9/30/2023
6302023804202310-Q 7/1/2023
3312023505202310-Q 4/1/2023
12312022223202310-K 12/31/2022
93020221104202210-Q 10/1/2022
6302022805202210-Q 7/2/2022
3312022506202210-Q 4/2/2022
12312021224202210-K 12/31/2021
93020211104202110-Q 10/2/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Pettiti GianlucaExecutive Vice President7282025Sell479.98400191,99210,735,677Form
1Pettiti GianlucaExecutive Vice President5132025Sell411.11400164,4449,359,711Form
2Pettiti GianlucaExecutive Vice President4302025Sell429.93300128,9799,960,156Form
3Boxer Michael ASVP and General Counsel3112025Sell532.523,7752,010,5375,759,762Form
4Chai Nelson 2212025Buy555.89168,8947,929,215Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.